#Netherlands #Menarini #NewAmsterdam #Naarden #Ubeslo

Positive Opinion for Ubeslo® and Evlarco® by CHMP

In a significant development for cardiovascular therapies, NewAmsterdam Pharma Company N.V. alongside Menarini Group announced that the Committee for Medicinal Products for Human Use (CHMP) has issued a favorable opinion recommending the market authorization for two innovative treatments: Ubeslo (monotherapy with obicetrapib) and Evlarco (fixed-dose combination of obicetrapib plus ezetimibe). This recommendation opens the doors for further regulatory processes leading to potential commercial availability in Europe.

The support from CHMP is derived from promising results unveiled in three pivotal Phase 3 clinical trials known as BROADWAY, BROOKLYN, and TANDEM. These studies have demonstrated obicetrapib's efficacy in significantly reducing LDL-C (low-density lipoprotein cholesterol) levels. Notably, patients receiving obicetrapib as a standalone treatment observed reductions of up to 40% in LDL-C when compared to a placebo, while those on the combination treatment experienced a staggering 50% reduction.

Dr. Michael Davidson, CEO of NewAmsterdam, celebrated this milestone, emphasizing that the favorable opinion not only marks progress for the company but also offers hope for patients struggling with elevated cholesterol levels who have not adequately responded to existing therapies. He expressed optimism about the drug's potential to fill the unmet medical need among patients at high risk for cardiovascular diseases.

Clinical Significance of Obicetrapib

The innovative drug class developed by NewAmsterdam aims to provide an alternative for patients who face challenges with traditional therapies. Obicetrapib operates through a unique mechanism designed to effectively lower LDL-C, which is a major contributor to cardiovascular risk. The oral administration of this treatment once a day, with or without food, adds to its appeal, promising ease of use for patients.

Additionally, NewAmsterdam continues to proactively conduct further research, as evidenced by their numerous ongoing Phase 3 trials, such as PREVAIL, which focuses on cardiovascular outcomes. These investigations are crucial in establishing the long-term benefits of obicetrapib in preventing serious cardiovascular events.

The Road Ahead

Looking forward, the decision by the European Commission is expected in the latter half of 2026, wherein it will deliberate on these recommendations. If approved, Ubeslo® and Evlarco® will be pivotal in transforming cardiovascular treatment strategies across the continent, potentially granting access to thousands of patients with high cholesterol.

Upon commercialization, Menarini Group will retain exclusive marketing rights for the two products in Europe, while NewAmsterdam will stand to benefit from tiered royalty agreements based on sales, capturing the financial upside related to their development successes.

Broader Context of Cardiovascular Diseases

Current statistics underscore the urgency of developing new therapies: cardiovascular diseases continue to be the leading global cause of mortality. Projections suggest that by 2050, a considerable percentage of the American adult population will be affected by various forms of cardiovascular diseases. Despite existing lipid-lowering therapies, many patients are unable to reach targeted LDL-C levels due to various factors, emphasizing the need for alternatives like Ubeslo®.

Conclusion

As NewAmsterdam Pharma and Menarini advance towards potential market authorization, the significance of this milestone cannot be overstated. If approved, these innovative therapies could provide new hope to those who are inadequately treated and struggling with cholesterol management, ultimately improving cardiovascular health outcomes on a large scale. Industry experts and patients alike await the European Commission's final verdict, hopeful for a future where effective treatment options are more readily available.